IMS 2022 | Moving BCMA-targeted agents to the frontline setting in myeloma & sequencing immunotherapies
Adam Sperling, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, comments on the idea of incorporating BCMA-targeted agents such as belantamab mafodotin and CAR-T therapy in the frontline treatment of multiple myeloma. BCMA-targeted agents have shown remarkable efficacy in the relapsed/refractory (R/R) setting, which has brought a lot of interest to moving these agents earlier in the treatment course of patients, and perhaps even replacing standard induction therapy and transplant. However, Dr Sperling explains that these standard therapies are already very effective and it will be difficult to prove that CAR-T therapy is better in the context of a clinical trial. Moving forward, Dr Sperling discusses the possibility of sequencing BCMA-targeted agents or sequencing a BCMA-targeted agent with another immunotherapy targeting another antigen such as GPRC5D. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
